ORMD 0901 is Being Developed as an Oral Dosage Form of a GLP1-analog Aimed
at Improving Glycemic Control in Adults With Type 2 Diabetes
JERUSALEM, Israel, September 16 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of oral drug delivery systems, announced today that it has launched pre-clinical trials of ORMD 0901, a GLP1-analog.
ORMD 0901 belongs to the Incretin family of drugs which helps to manage diabetes, including reduction in blood glucose levels and inhibiting glucagon secretion.
Incretins have been cited in causing regeneration of pancreatic insulin secreting cells, and in tissue protective properties including protection of the heart. GLP1 and analogs are associated with gradual weight loss, which is very desirable in diabetes patients.
"The launch of pre-clinical trials of ORMD 0901 and expansion of Oramed's platform marks the next strategic milestone for our company as we demonstrate the effectiveness of our oral delivery technology in yet another important family of polypeptide drugs for diabetes, that are until now only available in injection form," said Oramed CEO Nadav Kidron.
We plan to conduct the ORMD 0901 trials at Hadassah University Medical Center and they are expected to conclude by the end of 2008.
Oramed plans to launch phase 2b trials of ORMD 0801, its oral insulin capsule, in India in the first quarter of 2009.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.
For more information, please visit http://www.oramed.com
Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the
risks and uncertainties related to the progress, timing, cost, and results
of clinical trials and product development programs; difficulties or delays
in obtaining regulatory approval for our product candidates; competition
from other pharmaceutical or biotechnology companies; and the company's
ability to obtain additional funding required to conduct its research,
development and commercialization activities. Please refer to the company's
filings with the Securities and Exchange Commission for a comprehensive
list of risk factors that could cause actual results, performance or
achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no
obligation to update or revise any forward-looking statements.
Company and Investor Relation Contacts:
Ruder Finn Israel for Oramed
|SOURCE Oramed Pharmaceuticals Inc.|
Copyright©2008 PR Newswire.
All rights reserved